Mazdutide

Mazdutide: Clinical Guide to the GLP-1/Glucagon Dual Agonist

As the peptide pipeline evolves beyond single-pathway agents, Mazdutide is being positioned alongside advanced therapies such as Retatrutide and Tirzepatide, offering a differentiated mechanism that targets both caloric intake and energy expenditure. This clinical guide reviews its mechanism, trial data, and therapeutic potential for licensed practitioners tracking metabolic innovation. Note: This guide is intended for informational and research reference purposes only. Mazdutide is not approved for human therapeutic use outside of China's regulated clinical framework. Practitioners seeking research-grade compounds should verify the regulatory status and quality standards of any supplier in their jurisdiction.

What Is Mazdutide?

Mazdutide (IBI362) is a dual GLP-1/glucagon receptor agonist approved in China by the NMPA in June 2025 for weight management and in September 2025 for glycemic control, marketed under the brand name Xinermei®. International approval, including in the United States and Europe, remains pending. US Phase 2 trials are ongoing under Eli Lilly, with FDA approval estimated around 2028–2029. It is administered as a once-weekly subcutaneous injection and is designed to improve metabolic outcomes through complementary physiological pathways. Key characteristics include:

• Dual receptor targeting: GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR)
• Approved in China (NMPA, 2025) as Xinermei®; international approval pending
• Primary indications: obesity and non-alcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatotic liver disease (MASLD)
• Developed by Innovent Biologics

The Mazdutide peptide is part of a broader class of incretin-based therapies but distinguishes itself by incorporating glucagon-mediated metabolic effects, which enhance fat metabolism and energy utilization beyond what GLP-1 agonism alone can achieve. The China NMPA approval applies specifically to the pharmaceutical-grade Xinermei® formulation manufactured by Innovent Biologics. Research-grade Mazdutide sourced through other channels is a separate, unapproved compound intended for research purposes only and should not be used as a substitute for the approved product.

Mazdutide Mechanism of Action

Mazdutide's clinical relevance lies in its dual-agonist design, targeting both appetite regulation and metabolic expenditure. The pharmacology of its GLP-1 receptor activity is well characterized in incretin literature.

GLP-1 Receptor Agonism

Activation of the GLP-1 receptor plays a central role in regulating postprandial glucose levels and delaying gastric emptying. These metabolic responses are highly similar to those documented in the Semaglutide guide, but they represent only one facet of Mazdutide's broader therapeutic mechanism.

Glucagon Receptor Agonism

The addition of glucagon receptor activation introduces a distinct metabolic dimension:

• Increased energy expenditure through thermogenesis
• Enhanced lipolysis and fat oxidation
• Reduction in hepatic fat accumulation
• Potential improvement in liver inflammation markers

Dual Mechanism Advantage

By combining these pathways, Mazdutide simultaneously reduces caloric intake (via the GLP-1 pathway) and increases caloric burning (via the glucagon pathway). This dual action explains its promising results in both weight reduction and liver fat improvement, positioning it as a therapeutic candidate for MASLD, formerly known as NAFLD/NASH. In this context, Tirzepatide has comparatively limited liver-specific data, though researchers can evaluate its broader metabolic footprint in the Tirzepatide guide.

Mazdutide Clinical Trial Results

Clinical data for Mazdutide have expanded substantially through the GLORY Phase 3 program.

GLORY-1 Trial Overview

GLORY-1 is a Phase 3 clinical trial that evaluated Mazdutide in 610 adults with overweight or obesity in China, comparing once-weekly subcutaneous dosing at 4 mg and 6 mg against placebo over 48 weeks (Ji et al., N Engl J Med, 2025). The trial incorporated structured dose-escalation protocols to improve tolerability.

• Key outcomes: At the 6 mg weekly dose, patients achieved a mean body weight loss of approximately 15% at 48 weeks, placing it within the upper range of currently available incretin-based therapies. A clear dose-response relationship was observed across dosing groups. Compared to placebo, Mazdutide demonstrated superior absolute weight loss, percentage body weight reduction, and proportion of patients achieving ≥10% and ≥15% weight loss. Improvements in glycemic markers, including fasting glucose and HbA1c, were also observed in patients with type 2 diabetes.
• Liver outcomes: Mazdutide showed clinically meaningful reductions in hepatic fat fraction via imaging, improvements in liver enzymes (ALT and AST), and favorable trends in inflammatory and fibrosis-related biomarkers. Liver fat content was reduced by up to 80.2% in patients with high baseline hepatic fat, supporting its development as a potential therapeutic option for NASH and MASLD.

Trial Status and Regulatory Position

GLORY-1 was published in the New England Journal of Medicine in May 2025 — the first China-developed obesity drug study to appear in NEJM. China's NMPA approved Mazdutide for weight management in June 2025 and for glycemic control in September 2025 (brand name: Xinermei®). Phase 3 glycemic control trials (DREAMS-1 and DREAMS-2) were subsequently published in Nature. Internationally, US Phase 2 trials are ongoing; FDA approval is estimated around 2028–2029.

Mazdutide Dosage (Clinical Reference)

The dosing parameters below are drawn from published clinical trial protocols for reference purposes only. They do not constitute prescribing guidance. Research-grade Mazdutide is not equivalent to the approved Xinermei® formulation and is not intended for human therapeutic use. Phase 3 trials evaluated 4 mg and 6 mg once weekly, with a higher 9 mg dose evaluated in GLORY-2. A Phase 1 study in Western adults explored even higher doses, further characterizing the dose-response relationship in non-Asian populations (Bhattachar et al., Diabetes Obes Metab, 2025). Dose escalation is a critical component: gradual titration minimizes gastrointestinal adverse effects, allows physiological adaptation to GLP-1 receptor activation, and improves overall treatment adherence — mirroring established protocols used with other incretin therapies. Outside China, Mazdutide dosing should be interpreted for clinical research purposes only.

Mazdutide Benefits

Mazdutide introduces a dual-pathway metabolic strategy that simultaneously addresses multiple drivers of obesity and metabolic disease.

• Significant weight reduction: Clinical trial data demonstrate substantial weight loss across Phase 3 dosing groups, with the 9 mg dose in GLORY-2 achieving up to 20.1% body weight reduction. These results are comparable to the most effective incretin therapies currently approved.
• Increased energy expenditure: Unlike single-pathway GLP-1 agonists, Mazdutide activates the glucagon receptor to promote thermogenesis and caloric expenditure. This may help counteract metabolic adaptation often observed with weight-loss interventions.
• Liver fat reduction: Mazdutide consistently and substantially reduces hepatic fat content, supporting its role in managing NASH and related liver conditions. This liver-specific activity distinguishes it from other incretin agents with more limited hepatic data. Conversely, the mechanism outlined in the Cagrilintide guide targets amylin pathways, representing a complementary rather than a competing approach to metabolic regulation.
• Glycemic control: Improved glycemic parameters, including reductions in fasting glucose and HbA1c, highlight its utility in patients with type 2 diabetes, with Phase 3 glycemic data now published in Nature.
• Convenient weekly dosing: Once-weekly administration enhances patient adherence and simplifies treatment protocols compared to daily injectable therapies.

Overall, the Mazdutide peptide reflects a broader shift toward multi-receptor metabolic therapies designed to optimize both energy intake and expenditure.

Mazdutide Side Effects

Mazdutide's safety profile reflects its dual agonist activity, resulting in a combination of class-related gastrointestinal effects and metabolically driven responses. Current evidence from Phase 3 trials suggests most adverse events are predictable, manageable, and dose-dependent.

Gastrointestinal Effects

Gastrointestinal (GI) symptoms remain the most frequently reported adverse events and are consistent with the GLP-1 receptor agonist class, including agents such as Semaglutide and Tirzepatide. Common GI effects include:

• Nausea
• Vomiting
• Diarrhea
• Reduced appetite

These are most prominent during dose escalation, typically mild to moderate in severity, and diminish as tolerance develops. Structured dose titration significantly reduces incidence and severity.

Metabolic Effects Related to Glucagon

These effects are physiologically consistent with glucagon signaling and tend to stabilize as GLP-1-mediated insulinotropic effects balance glucagon activity over time. In patients with type 2 diabetes, overall glycemic control continues to improve. Observed or potential effects include:

• Temporary increases in fasting glucose during early treatment
• Increased lipolysis and fatty acid mobilization
• Elevated energy expenditure and thermogenesis
• Short-term variability in glucose homeostasis

Tolerability and discontinuation across Phase 3 trials were favorable, with discontinuation rates due to adverse events generally low and comparable to other incretin-based therapies. Researchers noted no increased cardiovascular risks in GLORY-1.

Mazdutide vs Retatrutide vs Tirzepatide vs Semaglutide

The metabolic peptide landscape is rapidly expanding. Below is a comparison of Mazdutide with other leading agents.

Therapy	Targets	Weight Loss (%)	NASH Data	Approval Status	Origin
Mazdutide	GLP-1 + Glucagon	~15%	Positive early data	Phase 3	China
Retatrutide	GIP + GLP-1 + Glucagon	Up to ~24% (early trials)	Emerging	Phase 3	USA
Tirzepatide	GIP + GLP-1	~20%	Limited	Approved (T2DM/obesity)	USA
Semaglutide	GLP-1	~15%	Some evidence	Approved	Denmark

• Mazdutide vs Retatrutide: According to data compiled in the Retatrutide guide, this molecule functions as a triple GIP/GLP-1/glucagon receptor agonist, whereas Mazdutide operates as a dual agonist. While Retatrutide may offer higher peak weight loss potential, Mazdutide provides a more targeted approach with substantially stronger liver-related outcomes.
• Mazdutide vs Tirzepatide: Tirzepatide targets GIP and GLP-1, whereas Mazdutide replaces GIP with glucagon — emphasizing energy expenditure over insulinotropic synergy and delivering markedly superior hepatic fat reduction.
• Mazdutide vs Semaglutide: Semaglutide relies solely on GLP-1 pathways, while Mazdutide adds glucagon-mediated metabolic enhancement. Both achieve comparable weight loss at approved doses, but Mazdutide's liver outcomes and its mechanism of energy expenditure clearly differentiate it.

For practitioners exploring the broader incretin and metabolic peptide pipeline, the peptides category covers adjacent research compounds.

FAQs — Mazdutide

1. What is Mazdutide approved for?

Mazdutide is approved in China by the NMPA for weight management (June 2025) and glycemic control in type 2 diabetes (September 2025), marketed as Xinermei®. It is not yet approved in the United States or Europe, where Phase 2 trials are ongoing. Research-grade Mazdutide sourced outside China's regulated framework is not the approved Xinermei® product and is not intended for human therapeutic use.

2. How does Mazdutide differ from Semaglutide?

Mazdutide includes both GLP-1 and glucagon receptor agonism, whereas Semaglutide targets only GLP-1. This added glucagon activity increases energy expenditure, enhances fat metabolism, and delivers substantially greater hepatic fat reduction — making it particularly relevant for patients with metabolic liver disease.

3. Is Mazdutide available for research?

Mazdutide is approved and commercially available in China under the brand name Xinermei®. Outside China, research-grade Mazdutide may be accessible through specialist suppliers in certain jurisdictions. Practitioners should verify regulatory compliance and supplier quality standards before procurement.

4. What weight loss can be expected?

Clinical trial data from GLORY-1 show approximately 15% body weight reduction at 48 weeks with 6 mg weekly dosing. GLORY-2 data with 9 mg dosing demonstrated up to 20.1% weight loss. These figures are from regulated pharmaceutical trials conducted with the approved formulation and do not apply to research-grade compounds.

References

1. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):1–29. doi:10.1038/s41392-024-01931-z
2. Ji L, Jiang H, Bi Y, et al. Once-weekly Mazdutide in Chinese adults with obesity or overweight. N Engl J Med. Published online May 24, 2025. doi:10.1056/nejmoa2411528
3. Bhattachar SN, Tham LS, Li Y, et al. Mazdutide reduces body weight in adults with overweight or obesity: a high-dose phase 1 trial. Diabetes Obes Metab. Published online August 20, 2025. doi:10.1111/dom.70040
4. Innovent Biologics. Mazdutide 9 mg achieves up to 20.1% weight loss in Chinese adults with obesity: GLORY-2 phase 3 study meets primary and all key secondary endpoints. Press release. Published November 19, 2025. https://www.prnewswire.com/news-releases/mazdutide-9-mg-achieves-up-to-20-1-weight-loss-in-chinese-adults-with-obesity-glory-2-study-meets-primary-and-all-key-secondary-endpoints-302620471.html

Disclaimer

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice. Mazdutide is not approved for human therapeutic use outside of China's regulated clinical framework. Practitioners should verify the regulatory status of any research-grade compound in their jurisdiction before use.